Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.40 |
| ▸ | PRKDC | P78527 | 2/20 | 0.38 |
| ▸ | CASR | P41180 | 9/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 4/20 | 0.35 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.35 |
| ▸ | MTOR | P42345 | 2/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3762187 | 0.88 | ATM (0.41) | BRD4PRKDCPIK3CAPIK3CGMTOR | |
| SCHEMBL3759849 | 0.88 | PRKDC (0.37) | BRD4PRKDCCASRPIK3CAPIK3CG | |
| SCHEMBL3766528 | 0.86 | PRKDC (0.52) | PRKDCALDH1A1PIK3CAPIK3CGMTOR | |
| SCHEMBL3759355 | 0.85 | PRKDC (0.41) | BRD4PRKDCALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL3763545 | 0.85 | RAB9A (0.46) | BRD4PRKDCALDH1A1SMN1; SMN2PIK3CA | |
| SCHEMBL3760075 | 0.84 | PRKDC (0.42) | BRD4PRKDCPIK3CAPIK3CGPIK3CD | |
| SCHEMBL3751898 | 0.84 | NPC1 (0.46) | PRKDCALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL3765924 | 0.84 | PIK3CA (0.44) | BRD4PRKDCALDH1A1PIK3CAPIK3CG | |
| SCHEMBL3763361 | 0.84 | PRKDC (0.42) | BRD4PRKDCPIK3CAPIK3CGPIK3CD | |
| SCHEMBL3769346 | 0.84 | MTOR (0.43) | BRD4PRKDCPIK3CAPIK3CGMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029570-B1 | FUSED THIOPHENE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-15 | — | — | EP | disclosed |
| US-8324204-B2 | Fused thiophene derivatives as kinase inhibitors | UCB PHARMA SA (BE) | 2012-12-04 | — | — | US | disclosed |
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305066-A1 | Fused Thiophene Derivatives as Kinase Inhibitors | PIKFYVE, PI4KA, PIK3CA | BRD4 1041/4885PRKDC 112/4885CASR 3484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.